Anbio Corp (NNNN) - Long-Term Liabilities to Capital

The financial model of Anbio Biotechnology relies on the sale of diagnostic systems and ancillary materials, with profitability standing at 0.00. Anbio Biotechnology is strengthening its status as a global expert in in-vitro diagnostics, earning the trust of medical centers through the quality of its products. Share price fluctuations on GURU.Markets confirm market interest in the developer of portable AI analyzers, which make rapid testing accessible in any pharmacy.

This ratio determines the proportion of long-term liabilities relative to equity, measuring the dependence of financial stability on external financing with a maturity horizon of over one year. For Anbio Biotechnology (NNNN), which is scaling the expansion of diagnostic systems across emerging markets, the trend of long-term debt to equity reflects the balance between aggressive market share growth and the risk of excessive leverage.